C

Corcept Therapeutics

develops cortisol-modulating therapies for Cushing's syndrome

Manager Pharmacokinetics

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeRedwood City, CA, USA$156.6k - $184.3kIn-person

About the Job

Requirements

  • The preferred education and experience profile is 0–3 years of industry experience and a PhD, PharmD, or MD degree with emphasis in pharmacokinetics, clinical pharmacology, or a related field.
  • Hands-on, in-depth knowledge of current versions of pharmacokinetic and data analysis software such as Excel, Phoenix WinNonlin, and GraphPad.
  • Hands-on, in-depth knowledge of current versions of PowerPoint and Word.
  • Strong written and oral communication skills.
  • Ability to adapt and solve problems, and confidence working in teams and independently.
  • Openness to training and coaching from team members.

Responsibilities

  • Support animal and human studies.
  • Conduct noncompartmental analyses of nonclinical and clinical data.
  • Plot and evaluate animal and human pharmacokinetic data.
  • Contribute to authoring pharmacokinetic and/or toxicokinetic reports.
  • Review bioanalytical and method validation reports.
  • Participate in supporting regulatory submissions, including INDs, IBs, and NDAs.
  • Adhere to agreed timelines to ensure prompt and accurate execution of deliverables.
  • Participate in developing and authoring study protocols, analysis plans, bioanalytical reports, and study reports.

About the Company

Corcept Therapeutics

develops cortisol-modulating therapies for Cushing's syndrome

Corcept Therapeutics develops and commercializes cortisol modulators to treat disorders caused by abnormal cortisol levels. Its core product, Korlym (mifepristone), blocks cortisol’s action by acting as a cortisol receptor antagonist and is approved for hypercortisolism in Cushing’s syndrome. The company differentiates itself with a dedicated focus on cortisol modulation, an extensive pipeline of proprietary molecules, and ongoing development beyond Korlym. Its goal is to improve outcomes for patients with cortisol-related disorders by expanding access to effective therapies and advancing new treatments.

Company size
501-1,000
Company stage
IPO
Headquarters
Menlo Park, CA
Founded
1998

Recently Posted Jobs

Explore more opportunities at Corcept Therapeutics

See more jobs